Investment will accelerate commercialization, strategic partnerships, product development and expansion of CellsBin's clinical and technical capabilities

此次投资将加速商业化进程、战略合作伙伴关系建立、产品开发，并拓展 CellsBin 的临床与技术能力。

BRANFORD, Conn.

康涅狄格州布兰福德

,

，

Sept. 22, 2026

2026年9月22日

/PRNewswire/ -- CellsBin, a biotechnology company pioneering Rare-Cell Biology™, today announced the closing of its Series A financing, led by 108 BioCapital.

/美通社/ -- 专注于开创性稀有细胞生物学™（Rare-Cell Biology™）的生物技术公司CellsBin今日宣布，已完成由108 BioCapital领投的A轮融资。

CellsBin is building a new observational layer for precision medicine through its Rare-Cell Intelligence™ Platform. By integrating advanced microfluidics, patented multimodal imaging, single-cell analysis and artificial intelligence, the platform makes rare cells visible, measurable and actionable—revealing biological signals that are often missed by conventional methods..

CellsBin 正通过其 Rare-Cell Intelligence™ 平台为精准医疗构建一个新的观测层。该平台整合了先进的微流控技术、专利多模态成像、单细胞分析和人工智能，使稀有细胞变得可见、可测量和可操作，从而揭示传统方法常常遗漏的生物信号。

The company's platform combines ultrasensitive rare-cell detection, high-dimensional cellular profiling, longitudinal biological monitoring, proprietary datasets and AI-driven analysis. Together, these capabilities are designed to help researchers and clinicians understand how therapeutic cells behave, how diseases evolve and why patients respond differently to cell therapy..

该公司的平台融合了超灵敏的稀有细胞检测、高维细胞图谱分析、纵向生物监测、专有数据集以及人工智能驱动的分析。这些能力协同作用，旨在帮助研究人员和临床医生理解治疗性细胞的行为、疾病的演变过程，以及患者对细胞疗法产生不同反应的原因。

CellsBin's initial applications focus on cell and gene therapy monitoring and hematologic cancers, with the broader goal of establishing Rare-Cell Biology™ as a foundational discipline across research, drug development and clinical medicine.

CellsBin 的初始应用专注于细胞和基因治疗监测以及血液系统癌症，其更广泛的目标是将 Rare-Cell Biology™ 确立为贯穿研究、药物开发和临床医学的基础学科。

'CellsBin is building a differentiated platform at the intersection of single-cell biology, artificial intelligence and translational medicine,' said Sasha Bakhru, Managing Partner of 108 BioCapital. 'Its ability to detect and characterize extremely rare cells could unlock important insights into therapeutic response, disease progression and patient outcomes.

“CellsBin 正在单细胞生物学、人工智能与转化医学的交叉领域构建一个差异化平台，”108 BioCapital 的管理合伙人 Sasha Bakhru 表示。“其检测和表征极稀有细胞的能力，有望揭示关于治疗反应、疾病进展及患者预后的关键洞见。”

We have been impressed by Ali and the CellsBin team's scientific rigor, platform vision and commitment to translating complex biology into actionable intelligence.'.

Ali和CellsBin团队在科学严谨性、平台愿景以及将复杂生物学转化为可操作智能方面的承诺给我们留下了深刻印象。

CellsBin will use the proceeds to accelerate commercial adoption, expand strategic and channel partnerships, advance its research and product-development roadmap, strengthen its clinical evidence base and grow its commercial, scientific and technical teams.

CellsBin 将利用所得款项加速商业化应用，拓展战略与渠道合作伙伴关系，推进其研发和产品开发路线图，夯实临床证据基础，并扩大其商业、科学和技术团队。

'We are excited to partner with CellsBin and support the company as it expands its network of strategic, clinical and commercial relationships,' said Shahryar Oveissi, General Partner of 108 BioCapital. 'We are already seeing strong interest from leading healthcare institutions in CellsBin's technology and its potential to create meaningful clinical impact.

108 BioCapital 的普通合伙人 Shahryar Oveissi 表示：“我们很高兴与 CellsBin 建立合作伙伴关系，并在其拓展战略、临床和商业关系网络的过程中提供支持。我们已经看到，领先的医疗机构对 CellsBin 的技术及其产生重大临床影响的潜力表现出浓厚的兴趣。”

We believe the 108 BioCapital ecosystem can help accelerate the company's next phase of growth.'.

我们相信，108 BioCapital 生态系统能够助力公司加速进入下一阶段的成长。

'This financing represents an important milestone in our mission to make rare cells visible, measurable and clinically actionable,' said Ali Kabiri, PhD, Co-founder and Chief Executive Officer of CellsBin. '108 BioCapital shares our conviction that rare cells contain critical biological information that can enable earlier, more precise and more confident decisions.

“这笔融资是我们使命中的一个重要里程碑，旨在让稀有细胞变得可见、可测量并具有临床可操作性，”CellsBin联合创始人兼首席执行官阿里·卡比里博士表示。“108 BioCapital与我们同样坚信，稀有细胞蕴含着关键的生物学信息，能够助力我们更早、更精准、更有信心地做出决策。”

This partnership will help us advance the Rare-Cell Intelligence™ Platform, deepen our market and channel reach, and build the capabilities required to establish Rare-Cell Biology™ as a new foundation for understanding disease and therapeutic response.'.

此次合作将帮助我们推进稀有细胞智能™平台，深化我们的市场和渠道覆盖，并建立将稀有细胞生物学™确立为理解疾病和治疗反应新基础所需的能力。

About CellsBin

关于 CellsBin

CellsBin is pioneering Rare-Cell Biology™ to reveal the rare cells that shape human health. It's Rare-Cell Intelligence™ Platform integrates advanced microfluidics, multimodal imaging, single-cell analysis and artificial intelligence to detect, characterize and monitor rare cells at scale. Through applications in precision diagnostics, therapeutic-cell monitoring and translational research, CellsBin is working to enable smarter decisions, earlier care and better lives..

CellsBin 正在开创稀有细胞生物学™，以揭示塑造人类健康的稀有细胞。其稀有细胞智能™ 平台整合了先进的微流控技术、多模态成像、单细胞分析和人工智能，能够大规模地检测、表征和监测稀有细胞。通过在精准诊断、治疗性细胞监测和转化研究中的应用，CellsBin 致力于实现更明智的决策、更早的干预和更美好的生活。

For more information, visit

更多信息，请访问

108.bio

108.bio

.

。

About 108 BioCapital

关于108 BioCapital

The 108 Bio Capital Fund seeks to generate superior returns through a differentiated investment strategy that leverages the founding team's exceptional technical expertise and deep networks within the US healthcare ecosystem. The Fund's approach is built upon decades of combined experience in biomedical technology, pharmaceutical development, medical device innovation, and regulatory navigation, enabling the identification and nurturing of breakthrough technologies that address significant unmet medical needs.

108 Bio Capital Fund 旨在通过差异化的投资策略创造卓越回报，该策略充分利用创始团队在美国医疗健康生态系统中卓越的技术专长和深厚的人脉网络。基金的方法建立在数十年综合经验的基础之上，涵盖生物医学技术、药物开发、医疗器械创新以及监管事务导航等领域，从而能够识别并培育解决重大未满足医疗需求的突破性技术。

This technical foundation, combined with proven track records in scaling MedTech ventures and executing successful exits, positions the Fund to capture value creation opportunities that may be overlooked by generalist investors lacking domain-specific expertise..

这一技术基础，结合在扩大医疗科技企业规模和成功退出方面的良好记录，使该基金能够抓住那些缺乏领域专业知识的普通投资者可能忽视的价值创造机会。

Media Contact

媒体联系人

Steve Ward

史蒂夫·沃德

Chief Financial Officer

首席财务官

[email protected]

[email protected]

SOURCE 108 Bio Captial

来源 108 Bio Capital

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示